目的分析老年多发性创伤骨折患者围术期下肢深静脉血栓形成(lower extremity deep venous thrombosis,LEDVT)的危险因素。方法收集2012年1月至2018年2月于本院行手术治疗的273例老年多发性创伤骨折患者的病历资料,根据患者围术期有无LED...目的分析老年多发性创伤骨折患者围术期下肢深静脉血栓形成(lower extremity deep venous thrombosis,LEDVT)的危险因素。方法收集2012年1月至2018年2月于本院行手术治疗的273例老年多发性创伤骨折患者的病历资料,根据患者围术期有无LEDVT,将其分为LEDVT组和非LEDVT组。统计所有患者的性别、年龄、格拉斯哥昏迷评分(Glasgow coma score,GCS)、病程、体质指数(body mass index,BMI)、创伤类型、骨折部位、骨折类型、手术时间、术中出血量、术后抗凝药物使用情况、术后卧床时间、合并症、吸烟史、饮酒史等资料。对以上资料进行单因素和非条件Logistic回归分析,筛选老年多发性创伤骨折患者围术期LEDVT形成的独立危险因素。结果 273例患者中,61例(25.95%)发生LEDVT。单因素分析结果显示:年龄、BMI、骨折类型、手术时间、术后是否使用抗凝药物、术后卧床时间、是否合并糖尿病、有无吸烟史均为老年多发性创伤骨折患者围术期LEDVT的影响因素(P_均<0.05)。非条件Logistic回归分析显示:年龄≥75岁、BMI> 30 kg/m^2、手术时间≥2 h、术后卧床时间≥5 d、合并糖尿病、有吸烟史均为老年多发性创伤骨折患者围术期LEDVT的独立危险因素(P_均<0.05)。结论老年多发性创伤骨折患者围术期LEDVT较为常见,临床上需根据患者年龄、BMI、手术时间、术后卧床时间、合并糖尿病及吸烟史等采取必要的干预措施,尽量避免LEDVT的发生。展开更多
The T-box transcription factor T-bet （Tbx21） has emerged as a key regulator of type 1-like immunity, playing critical roles in the establishment and/or maintenance of effector call fates in T and B lymphocytes, as w...The T-box transcription factor T-bet （Tbx21） has emerged as a key regulator of type 1-like immunity, playing critical roles in the establishment and/or maintenance of effector call fates in T and B lymphocytes, as well as dendritic cells and natural killer calls. Several autoimmune diseases, especially those classically considered related to T helper 1 （Thl） immunity, appear to require T-bet, at least as judged in mouse models. This review summarizes a current understanding of T-bet＇s role in immunity, as wall as its importance in autoimmunity, with implications for therapeutic intervention.展开更多
AIM: To evaluate the efficiency and safety of combined recombinant human growth hormone (rhGH) and lactulose for treatment and/or prevention of multiple organ dysfunction in patients with chronic severe hepatitis B. M...AIM: To evaluate the efficiency and safety of combined recombinant human growth hormone (rhGH) and lactulose for treatment and/or prevention of multiple organ dysfunction in patients with chronic severe hepatitis B. METHODS: Forty-eight inpatients with chronic severe hepatitis B were randomly divided into rhGH group (n = 28)and control group (n = 20). In rhGH group, 4-4.5 IU of rhGH was injected intramuscularly once daily for 2-4 wk,and 100 mL of enema containing 30 mL of lactulose, 2 g of metronidazole and 0.9% saline was administered every 2 d for 2-4 wk. Their symptoms and complications were noted. Liver and kidney functions were analyzed by an Olympus analyzer. Serum GH, IGF-1, IGFBP1 and IGFBP3 were measured by ELISA.RESULTS: Clinical symptoms of 90% of these patients in rhGH group were obviously improved. The total effectiveness in rhGH group was better than that in control group (75% vs40%, P＜0.05). After 2- and 4-wk treatment of rhGH respectively, serum albumin (26.1±4.1 vs 30.2±5.3,31.9±5.1 g/L), prealbumin (79.6±28.0 vs 106.6±54.4,108.4±55.0 g/L), cholesterol (76.3±16.7 vs 85.6±32.3,96.1±38.7 mg/dL), and IGFBP1 (56.8±47.2 vs 89.7±50.3ng/mL after 2 wk) were significantly increased compared to control group (P＜0.05). However, serum GH was decreased. The increase of serum IGF1 and IGFBP3 after rhGH treatment was also observed.CONCLUSION: rhGH in combination with lactulose may be beneficial to the prevention and treatment of multiple organ dysfunction in patients with chronic severe hepatitis.展开更多
文摘目的分析老年多发性创伤骨折患者围术期下肢深静脉血栓形成(lower extremity deep venous thrombosis,LEDVT)的危险因素。方法收集2012年1月至2018年2月于本院行手术治疗的273例老年多发性创伤骨折患者的病历资料,根据患者围术期有无LEDVT,将其分为LEDVT组和非LEDVT组。统计所有患者的性别、年龄、格拉斯哥昏迷评分(Glasgow coma score,GCS)、病程、体质指数(body mass index,BMI)、创伤类型、骨折部位、骨折类型、手术时间、术中出血量、术后抗凝药物使用情况、术后卧床时间、合并症、吸烟史、饮酒史等资料。对以上资料进行单因素和非条件Logistic回归分析,筛选老年多发性创伤骨折患者围术期LEDVT形成的独立危险因素。结果 273例患者中,61例(25.95%)发生LEDVT。单因素分析结果显示:年龄、BMI、骨折类型、手术时间、术后是否使用抗凝药物、术后卧床时间、是否合并糖尿病、有无吸烟史均为老年多发性创伤骨折患者围术期LEDVT的影响因素(P_均<0.05)。非条件Logistic回归分析显示:年龄≥75岁、BMI> 30 kg/m^2、手术时间≥2 h、术后卧床时间≥5 d、合并糖尿病、有吸烟史均为老年多发性创伤骨折患者围术期LEDVT的独立危险因素(P_均<0.05)。结论老年多发性创伤骨折患者围术期LEDVT较为常见,临床上需根据患者年龄、BMI、手术时间、术后卧床时间、合并糖尿病及吸烟史等采取必要的干预措施,尽量避免LEDVT的发生。
文摘The T-box transcription factor T-bet （Tbx21） has emerged as a key regulator of type 1-like immunity, playing critical roles in the establishment and/or maintenance of effector call fates in T and B lymphocytes, as well as dendritic cells and natural killer calls. Several autoimmune diseases, especially those classically considered related to T helper 1 （Thl） immunity, appear to require T-bet, at least as judged in mouse models. This review summarizes a current understanding of T-bet＇s role in immunity, as wall as its importance in autoimmunity, with implications for therapeutic intervention.
基金Supported by the Foundation of Beijing Science and Technology Commission, No. H010210110129
文摘AIM: To evaluate the efficiency and safety of combined recombinant human growth hormone (rhGH) and lactulose for treatment and/or prevention of multiple organ dysfunction in patients with chronic severe hepatitis B. METHODS: Forty-eight inpatients with chronic severe hepatitis B were randomly divided into rhGH group (n = 28)and control group (n = 20). In rhGH group, 4-4.5 IU of rhGH was injected intramuscularly once daily for 2-4 wk,and 100 mL of enema containing 30 mL of lactulose, 2 g of metronidazole and 0.9% saline was administered every 2 d for 2-4 wk. Their symptoms and complications were noted. Liver and kidney functions were analyzed by an Olympus analyzer. Serum GH, IGF-1, IGFBP1 and IGFBP3 were measured by ELISA.RESULTS: Clinical symptoms of 90% of these patients in rhGH group were obviously improved. The total effectiveness in rhGH group was better than that in control group (75% vs40%, P＜0.05). After 2- and 4-wk treatment of rhGH respectively, serum albumin (26.1±4.1 vs 30.2±5.3,31.9±5.1 g/L), prealbumin (79.6±28.0 vs 106.6±54.4,108.4±55.0 g/L), cholesterol (76.3±16.7 vs 85.6±32.3,96.1±38.7 mg/dL), and IGFBP1 (56.8±47.2 vs 89.7±50.3ng/mL after 2 wk) were significantly increased compared to control group (P＜0.05). However, serum GH was decreased. The increase of serum IGF1 and IGFBP3 after rhGH treatment was also observed.CONCLUSION: rhGH in combination with lactulose may be beneficial to the prevention and treatment of multiple organ dysfunction in patients with chronic severe hepatitis.
